Truist sets USD 55.00 target for Alkermes stock
Alpha Vantage · ad-hoc-news.de · · AI-summarised by FinFlash
Truist resumed coverage of Alkermes with a Buy rating and a $55.00 price target, implying 33.19% upside from the Nasdaq-listed stock's $41.22 price. The company, which develops medicines for central nervous system disorders, has a $6.9 billion market capitalization and a trailing P/E of 107.62.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.